Scorpion Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
140
- Latest Deal Type
-
M&A
- (Announced)
- Latest Deal Amount
-
$2.5B
- Investors
-
26
Scorpion Therapeutics General Information
Description
Operator of a precision therapeutics company intended for cancer treatments. The company integrates technologies across target discovery, medicinal chemistry, and translational medicine to deliver a pipeline of targeted small-molecule drugs that overcome the limitations of existing treatments, thereby executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology, enabling healthcare professionals to treat patients with novel treatments.
Contact Information
Website
www.scorpiontx.comCorporate Office
- 1 Winthrop Square
- Suite 400
- Boston, MA 02110
- United States
Corporate Office
- 1 Winthrop Square
- Suite 400
- Boston, MA 02110
- United States
Scorpion Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 11-Jan-2025 | $2.5B | Announced | Generating Revenue | ||
| 3. Later Stage VC (Series C) | 16-Jul-2024 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 07-Jan-2021 | $162M | $270M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 26-Oct-2020 | $108M | $108M | Completed | Clinical Trials - Phase 1 |
Scorpion Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C2 | ||||||||
| Series C1 | ||||||||
| Series B | ||||||||
| Series A2 | 42,784,910 | $0.001000 | $1.3 | $1.3 | 1x | $1.3 | 12.85% | |
| Series A1 | 52,837,500 | $0.001000 | $1 | $1 | 1x | $1 | 15.87% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Scorpion Therapeutics Comparisons
Industry
Financing
Details
Scorpion Therapeutics Competitors (5)
One of Scorpion Therapeutics’s 5 competitors is Flare Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Flare Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| SEngine Precision Medicine | Formerly VC-backed | Bothell, WA | ||||
| Relay Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| OnKure Therapeutics | Formerly VC-backed | Boulder, CO |
Scorpion Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Scorpion Therapeutics Patents
Scorpion Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4499635-A1 | Methods of synthesizing egfr inhibitors | Pending | 24-Mar-2022 | ||
| AU-2022325819-A1 | Compounds that inhibit pi3k isoform alpha and methods for treating cancer | Pending | 09-Aug-2021 | ||
| EP-4363414-A1 | Compounds that inhibit pi3k isoform alpha and methods for treating cancer | Pending | 09-Aug-2021 | ||
| CA-3227902-A1 | Compounds that inhibit pi3k isoform alpha and methods for treating cancer | Pending | 09-Aug-2021 | ||
| US-20240343728-A1 | Compounds that inhibit pi3k isoform alpha and methods for treating cancer | Pending | 09-Aug-2021 | C07D473/32 |
Scorpion Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Scorpion Therapeutics Investors (26)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Avoro Capital | Venture Capital | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority | ||
| Lightspeed Venture Partners | Venture Capital | Minority | ||
| Olive Tree Capital | Venture Capital | Minority |
Scorpion Therapeutics FAQs
-
When was Scorpion Therapeutics founded?
Scorpion Therapeutics was founded in 2020.
-
Where is Scorpion Therapeutics headquartered?
Scorpion Therapeutics is headquartered in Boston, MA.
-
What is the size of Scorpion Therapeutics?
Scorpion Therapeutics has 140 total employees.
-
What industry is Scorpion Therapeutics in?
Scorpion Therapeutics’s primary industry is Drug Discovery.
-
Is Scorpion Therapeutics a private or public company?
Scorpion Therapeutics is a Private company.
-
What is the current valuation of Scorpion Therapeutics?
The current valuation of Scorpion Therapeutics is .
-
What is Scorpion Therapeutics’s current revenue?
The current revenue for Scorpion Therapeutics is .
-
How much funding has Scorpion Therapeutics raised over time?
Scorpion Therapeutics has raised $420M.
-
Who are Scorpion Therapeutics’s investors?
Avoro Capital, Fidelity Management & Research Company, Frazier Healthcare Partners, Lightspeed Venture Partners, and Olive Tree Capital are 5 of 26 investors who have invested in Scorpion Therapeutics.
-
Who are Scorpion Therapeutics’s competitors?
Flare Therapeutics, SEngine Precision Medicine, Relay Therapeutics, Sarepta Therapeutics, and OnKure Therapeutics are competitors of Scorpion Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
